Nautilus Biotechnology, Inc.
NASDAQ:NAUTBiotechnology
+$0.05 today
- Market cap
- $309.51M
- Beta
- 0.75
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$0.45
Volume 4.55M
Average 0.40M
NAUT Short-term Investments
Marketable securities and deposits the company expects to convert to cash within a year.
Nautilus Biotechnology, Inc.NASDAQ: NAUT
Short-term Investments · Q1 FY2026 · quarter ended Mar 2026
Short-term investments falls 23.0% from a year ago
Short-term investments stood at $81.24M at the end of Q1 FY2026, down 23.0% from a year earlier and down 10.7% from the prior quarter. Over 3 fiscal years it compounded at +9.2% a year.
Context
- Short-term investments amounted to 45.7% of total assets at the end of Q1 FY2026, down 0.7 pp from a year earlier.
- Short-term investments increased in 1 of the last 3 fiscal years.
What to watch
Whether short-term investments keeps falling in the next quarterly balance sheet after a -23.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 91.02M USD
- Year-over-year change
- -11.0%
- 4-year CAGR
- -13.2%
| Period | Period end | Short-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 91.02M | -11.0% |
| FY2024 | 2024-12-31 | 102.25M | -33.6% |
| FY2023 | 2023-12-31 | 154.02M | +120.2% |
| FY2022 | 2022-12-31 | 69.95M | -56.3% |
| FY2021 | 2021-12-31 | 160.11M | — |
Short-term Investments vs competitors
How NAUT compares with its peers on the latest reported figures
- NAUT's Mar 2026 short-term investments of $81.24M is the 5th highest of the 11 companies compared; the peer median is $51.58M.
- Its year-over-year change of -23.0% is the 4th highest of 7, against a peer median of -27.4%.
- Short-term investments amounts to 45.7% of total assets for NAUT, versus a peer median of 20.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $195.48M | +189.1% | +69.1% | 83.0% | |
| Mar 2026 | $128.85M | -3.2% | -8.6% | 40.9% | |
| Mar 2026 | $109.37M | — | +10.3% | 0.1% | |
| Mar 2026 | $95.97M | -39.9% | -35.7% | 43.2% | |
| Mar 2026 | $81.24M | -23.0% | +9.2% | 45.7% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | $67.91M | -15.0% | +34.4% | 63.0% |
| Mar 2026 | $35.25M | -62.0% | — | 54.8% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
ZURAZura Bio Limited | Mar 2026 | $0 | — | — | 0.0% |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding NAUT) | $51.58M | -27.4% | +10.3% | 20.5% | |
Competitors are the stored peer set for NAUT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 185.62M | 114.52M | 19.4M | 27.65M | 12.39M |
| Short-term Investments | 160.11M | 69.95M | 154.02M | 102.25M | 91.02M |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 3.42M | 2.93M | 2.56M |
| Total Current Assets | 349.22M | 187.21M | 176.84M | 132.83M | 105.96M |
| Property, Plant & Equipment (Net) | 31.86M | 32.57M | 36.9M | 32.33M | 31.23M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 16.37M | 129.17M | 90.65M | 76.41M | 52.74M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 997K | 1.11M | 1.18M | 1.18M | 1.18M |
| Total Non-current Assets | 49.23M | 162.84M | 128.73M | 109.92M | 85.15M |
| Total Assets | 398.45M | 350.05M | 305.57M | 242.74M | 191.11M |
| Account Payables | 1.72M | 1.27M | 1.64M | 987K | 943K |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 388K | 438K | 2.97M | 1.86M | 2.7M |
| Total Current Liabilities | 5.81M | 6.79M | 9.12M | 7.63M | 7.95M |
| Long-term Debt | 0 | 0 | 0 | 0 | 26.19M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 29.06M | 28.34M | 31.09M | 26.38M | 26.19M |
| Total Liabilities | 34.87M | 35.13M | 40.21M | 34.01M | 34.14M |
| Common Stock | 12K | 12K | 13K | 13K | 13K |
| Retained Earnings | (80.64M) | (138.56M) | (202.24M) | (273.02M) | (332.02M) |
| Accumulated OCI | (184K) | (1.85M) | (255K) | 57K | 243K |
| Other Stockholders Equity | (0) | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 363.58M | 314.92M | 265.35M | 208.73M | 156.97M |
| Total Debt | 30.03M | 30.33M | 34.63M | 30.48M | 30.02M |
| Net Debt | (155.59M) | (84.2M) | 15.23M | 2.83M | 17.63M |
Nautilus Biotechnology, Inc.
NASDAQ:NAUT
Intrinsic Alpha fair value
Locked
Current Price
$2.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.